Bestatin therapy of patients with atopic dermatitis
DOI:
https://doi.org/10.2340/0001555563549552Abstract
Ten adult patients with severe atopic dermatitis were treated for three months with estatin, which is a metabolite of Streptomyces olivoreticuli. Bestatin has been shown to increase tumor resistance in mice, augment a variety of immune responses and to reduce the level of IgE in non-atopic healthy persons. During bestatin therapy we were not able to see any clinical change of the atopic dermatitis. No influence was found on the concentration of IgE in serum and the number of eosinophils in blood. The percentage of T lymphocytes and the Con A-induced suppressor cell activity was not changed. (Received June 18, 1983.)Downloads
Download data is not yet available.
Downloads
Published
1983-11-01
How to Cite
Thestrup-Pedersen, K., Cramers, M., Kongsholm, H., & Zachariae, H. (1983). Bestatin therapy of patients with atopic dermatitis. Acta Dermato-Venereologica, 63(6), 549–552. https://doi.org/10.2340/0001555563549552
Issue
Section
Articles
License
LicenseAll digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
